uniQure N.V. (NASDAQ:QURE) Director Jack Kaye Sells 2,112 Shares

uniQure N.V. (NASDAQ:QURE - Get Free Report) Director Jack Kaye sold 2,112 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the transaction, the director now owns 20,439 shares in the company, valued at approximately $295,343.55. This trade represents a 9.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

uniQure Trading Up 1.9%

Shares of QURE traded up $0.27 during midday trading on Tuesday, hitting $14.22. 852,314 shares of the stock were exchanged, compared to its average volume of 1,953,833. uniQure N.V. has a 52-week low of $3.73 and a 52-week high of $19.18. The stock has a fifty day simple moving average of $14.29 and a 200 day simple moving average of $13.99. The company has a current ratio of 11.99, a quick ratio of 11.99 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE - Get Free Report) last released its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. The firm had revenue of $1.57 million during the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. On average, sell-side analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Cantor Fitzgerald upgraded uniQure to a "strong-buy" rating in a research report on Monday, May 19th. Wells Fargo & Company decreased their target price on uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research report on Friday, February 28th. Guggenheim restated a "buy" rating and issued a $28.00 target price on shares of uniQure in a research report on Monday, May 12th. Chardan Capital restated a "buy" rating and issued a $38.00 target price on shares of uniQure in a research report on Friday, May 30th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price target on shares of uniQure in a report on Thursday, May 29th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $37.82.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of QURE. Twin Tree Management LP purchased a new position in uniQure in the fourth quarter valued at $77,000. Mraz Amerine & Associates Inc. purchased a new position in uniQure in the first quarter valued at $106,000. OMERS ADMINISTRATION Corp purchased a new stake in uniQure during the 1st quarter worth about $152,000. ADAR1 Capital Management LLC purchased a new stake in uniQure during the 4th quarter worth about $177,000. Finally, Wells Fargo & Company MN lifted its holdings in uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock worth $217,000 after buying an additional 1,503 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.